# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-26-197877
Filing Date
2026-04-30
Accepted
2026-04-30 17:22:09
Documents
11

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | sndx-20260430.htm iXBRL | DEFA14A | 21553
2 | GRAPHIC | img181013684_0.jpg | GRAPHIC | 346975
3 | GRAPHIC | img181013684_1.jpg | GRAPHIC | 271532
| Complete submission text file | 0001193125-26-197877.txt |  | 1565586

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | sndx-20260430.xsd | EX-101.SCH | 7011
14 | EXTRACTED XBRL INSTANCE DOCUMENT | sndx-20260430_htm.xml | XML | 1305

Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37708 | Film No.: 26927332
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)